Cytokeratin 8 (CARD2, CK8, CYK8, CYKER, Cytokeratin Endo A, DreK8, EndoA, K2C8, K8, Keratin 8, Krt 2.8, KRT8, Type-II Keratin Kb8) (APC)
Référence 168752-AF-APC-100ul
Conditionnement : 100ul
Marque : US Biological
168752-AF-APC Cytokeratin 8 (CARD2, CK8, CYK8, CYKER, Cytokeratin Endo A, DreK8, EndoA, K2C8, K8, Keratin 8, Krt 2.8, KRT8, Type-II Keratin Kb8) (APC)
Clone Type
PolyclonalHost
mouseSource
humanSwiss Prot
P05787 (Human)Isotype
IgG1Grade
PurifiedApplications
IF IHC IP WBCrossreactivity
Hu Rt ZeShipping Temp
Blue IceStorage Temp
4°C Do Not FreezeCytokeratin 8 (CK8) belongs to the type II (or B or basic) subfamily of high molecular weight cytokeratins and exists in combination with cytokeratin 18 (CK18). CK8 is primarily found in the non-squamous epithelia and is present in majority of adenocarcinomas and ductal carcinomas. It is absent in squamous cell carcinomas. Hepatocellular carcinomas are defined by the use of antibodies that recognize only cytokeratin 8 and 18. CK8 exists on several types of normal and neoplastic epithelia, including many ductal and glandular epithelia such as colon, stomach, small intestine, trachea, and esophagus as well as in transitional epithelium. Anti-CK8 does not react with skeletal muscle or nerve cells. Epithelioid sarcoma, chordoma, and adamantinoma show strong positivity corresponding to that of simple epithelia (with antibodies against CK8, CK18 and CK19). Reportedly, anti-CK8 is useful for the differentiation of lobular (“ring-like, perinuclear”) from ductal (“peripheral-predominant”) carcinoma of the breast.||Applications: |Suitable for use in Immunofluorescence, Flow Cytometry (Not Tested), Western Blot, Immunoprecipitation, Immunohistochemistry. Other applications not tested.||Recommended Dilution:|Flow Cytometry (Not Tested): 0.5-1ug/million cells |Immunofluorescence: 1-2ug/ml |Immunoprecipitation: 1-2ug/500ug protein |Western Blot: 0.5-1.0ug/ml |Immunohistochemistry: Frozen & formalin-fixed: 0.5-1.0ug/ml for 30 min at RT|(Staining of formalin-fixed tissues requires boiling tissue sections in 10mM Citrate Buffer, pH 6.0, for 10-20 min followed by cooling at RT for 20 minutes|Optimal dilutions to be determined by the researcher.||Positive Control:|MCF-7 or A431 cells. Skin, Colon, lung or breast carcinoma||Storage and Stability:|May be stored at 4°C before opening. DO NOT FREEZE! Stable at 4°C as an undiluted liquid. Dilute only prior to immediate use. Stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer. APC is light sensitive.||Note: Applications are based on unconjugated antibody.